significant changes

Severe adverse effects were reported in 48 (30%) patients, including unexpected sudden death with epilepsy but considered unrelated to the study drug. There were serious adverse effects considered possibly related to the use of cannabidiol in 20 patients and included status epilepticus, diarrhea, pneumonia and weight loss CBD Gummies. None of the cases of status epilepticus was associated with previous reductions in the doses of

basal antiepileptic drugs or cannabidiol. There were no clinically significant changes in white or red blood cell counts or in renal function. Five (3%) patients had mild to moderate thrombocytopenia; one (1%) patient had severe thrombocytopenia (8 × 10⁹ / L) that resolved when the valproate was discontinued.